DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have earned an average recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $98.00.

Several equities research analysts have weighed in on DXCM shares. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company increased their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. boosted their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Finally, Stifel Nicolaus increased their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd.

DexCom Price Performance

DexCom stock opened at $75.26 on Friday. The stock has a market capitalization of $29.40 billion, a price-to-earnings ratio of 45.07, a PEG ratio of 2.46 and a beta of 1.12. DexCom has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock’s 50 day moving average price is $74.19 and its two-hundred day moving average price is $83.40.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the second quarter worth about $25,000. Sachetta LLC raised its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Riverview Trust Co lifted its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. DT Investment Partners LLC grew its holdings in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares during the period. Finally, RPg Family Wealth Advisory LLC purchased a new stake in DexCom in the third quarter worth $57,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.